Cambrex Co. (CBM) Receives $46.75 Consensus Target Price from Brokerages

Cambrex Co. (NYSE:CBM) has received a consensus rating of “Buy” from the seven research firms that are covering the stock, MarketBeat Ratings reports. Two analysts have rated the stock with a hold recommendation, three have issued a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $47.80.

CBM has been the subject of several research reports. ValuEngine upgraded Cambrex from a “hold” rating to a “buy” rating in a research report on Saturday, May 4th. Craig Hallum cut their price objective on Cambrex from $71.00 to $45.00 and set a “buy” rating for the company in a research report on Thursday, February 14th. Zacks Investment Research upgraded Cambrex from a “hold” rating to a “buy” rating and set a $44.00 price objective for the company in a research report on Monday, February 11th. Jefferies Financial Group cut shares of Cambrex from a “buy” rating to a “hold” rating and set a $43.00 target price for the company. in a research note on Friday, February 22nd. Finally, Robert W. Baird cut shares of Cambrex from an “outperform” rating to a “neutral” rating and set a $44.00 target price for the company. in a research note on Friday, May 3rd. They noted that the move was a valuation call.

In other Cambrex news, COO Shawn Cavanagh sold 6,769 shares of Cambrex stock in a transaction that occurred on Friday, February 15th. The shares were sold at an average price of $37.60, for a total value of $254,514.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Gregory Sargen sold 5,802 shares of Cambrex stock in a transaction that occurred on Friday, February 15th. The stock was sold at an average price of $37.45, for a total transaction of $217,284.90. The disclosure for this sale can be found here. 1.41% of the stock is currently owned by insiders.



Hedge funds have recently added to or reduced their stakes in the business. Marshall Wace LLP purchased a new stake in shares of Cambrex during the 1st quarter valued at $30,000. Enlightenment Research LLC purchased a new stake in shares of Cambrex during the 4th quarter valued at $30,000. Flagship Harbor Advisors LLC grew its stake in shares of Cambrex by 2,725.8% during the 1st quarter. Flagship Harbor Advisors LLC now owns 876 shares of the biotechnology company’s stock valued at $34,000 after buying an additional 845 shares during the period. Private Capital Group LLC grew its stake in shares of Cambrex by 25.9% during the 4th quarter. Private Capital Group LLC now owns 1,503 shares of the biotechnology company’s stock valued at $57,000 after buying an additional 309 shares during the period. Finally, NumerixS Investment Technologies Inc purchased a new stake in shares of Cambrex during the 4th quarter valued at $79,000.

Shares of Cambrex stock traded down $0.52 during trading on Wednesday, hitting $43.79. 185,600 shares of the company were exchanged, compared to its average volume of 364,898. The company has a debt-to-equity ratio of 0.79, a current ratio of 2.96 and a quick ratio of 2.01. Cambrex has a fifty-two week low of $33.80 and a fifty-two week high of $69.43. The company has a market capitalization of $1.48 billion, a P/E ratio of 15.81, a P/E/G ratio of 3.44 and a beta of 2.41.

Cambrex (NYSE:CBM) last issued its quarterly earnings data on Thursday, May 2nd. The biotechnology company reported $0.31 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.21 by $0.10. Cambrex had a return on equity of 12.25% and a net margin of 14.35%. The firm had revenue of $159.46 million during the quarter, compared to the consensus estimate of $159.71 million. During the same period in the previous year, the firm posted $0.72 EPS. The company’s quarterly revenue was up 13.0% compared to the same quarter last year. As a group, research analysts expect that Cambrex will post 1.28 EPS for the current fiscal year.

Cambrex Company Profile

Cambrex Corporation, a life sciences company, provides various products and services for the development and commercialization of new and generic therapeutics worldwide. Its products comprise active pharmaceutical ingredients and pharmaceutical intermediates that are used in the production of prescription and over-the-counter drug products, as well as finished dosage forms.

Further Reading: What is the price-sales ratio?

Receive News & Ratings for Cambrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex and related companies with MarketBeat.com's FREE daily email newsletter.